NEWTOWN, Pa., July 23, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Encompass Health Corporation ("Encompass") (NYSE: EHC), resulting from allegations of providing potentially misleading information to the investing public.If you are an Encompass investor who suffered a substantial loss and would like to learn more, you can provide your contact information and trading details HERE.You can also contact attorney Eric Lechtzin of Edels ...

NEWMARKET, Ontario, July 23, 2025 (GLOBE NEWSWIRE) -- AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the “Company” or “AirBoss”) today announced that it will release its second quarter 2025 results after markets close on August 7th, 2025. The release will be followed by a conference call to discuss the results on Friday, August 8, 2025, at 9:00 am ET. SECOND QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL DETAILS: DATE: Friday, August 8, 2025TIME: 9:00 am ETDIAL-IN NUMBER: 1-833-821-0163 or 1-647-846-229 ...

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, July 7th:Verona Pharma (VRNA) : This company which is focused on developing and commercializing innovative therapeutics for the treatment of patients burdened with chronic respiratory diseases with significant unmet medical needs, has a Zacks Rank #1(Strong Buy), and witnessed the Zacks Consensus Estimate for its current year earnings increasing 37.5% over the last 60 days.Verona Pharma’s shares gained 69% ...

Core Viewpoint - Quipt Home Medical Corp. has acquired a durable medical equipment provider owned by Ballad Health, marking a strategic milestone that enhances its partnerships with healthcare systems and expands its service offerings in respiratory care [1][2]. Acquisition Details - The acquisition includes a purchase price of $1.6 million, with the Acquiree reporting unaudited revenue of $6.6 million for the fiscal year ended June 30, 2025, serving over 12,500 patients annually [1][5]. - The Acquiree operates four branch locations across East Tennessee and Southwest Virginia, providing a comprehensive portfolio of respiratory, oxygen, mobility, and home medical products [2][5]. Strategic Implications - The acquisition is expected to facilitate seamless post-acute care coordination through a Preferred Provider Agreement with Ballad Health, integrating Quipt into the care delivery model [2][4]. - Management anticipates that the transaction will establish a scalable playbook for future partnerships with health systems nationwide, enhancing organic growth and reducing patient readmissions [4][5]. Financial Outlook - The management expects the Acquiree's Adjusted EBITDA margin to align with Quipt's historical range within two quarters, driven by operational efficiencies [5]. - The acquisition was completed using cash on hand, maintaining a conservative balance sheet and allowing for future financial flexibility [4][5]. Market Context - The service area of the Acquiree is experiencing a rapidly growing senior population, with the 65+ age cohort expected to grow by 10.2% by 2028, indicating a strong demand for home medical services [5].

Core Viewpoint - Moderna has experienced a significant decline in stock performance and sales due to waning demand for its coronavirus vaccine, losing over 90% of its value since its peak in 2021 [1][2][7] Company Background - Moderna initially gained prominence during the pandemic, generating up to $18.4 billion in annual revenue from its coronavirus vaccine, leading to substantial profits [4] - The company has since faced challenges as vaccine demand decreased, and its RSV vaccine sales have also underperformed [5] Cost Management and R&D Focus - In response to declining sales, Moderna has initiated a cost realignment plan aiming to reduce GAAP operating costs by up to $1.7 billion by 2027 [6] - The company is prioritizing research and development, with plans to launch as many as 10 new products in the next three years, although these launches are not guaranteed [6] Future Product Pipeline - Moderna anticipates having around 10 products on the market in 10 years, including several cancer vaccines and a cytomegalovirus vaccine, along with potential respiratory virus vaccines [11] - The company has a strong success rate in late-stage trials, with an 83% probability of success in phase 3 trials compared to the industry average of 69% [12] Revenue Projections - By 2028, Moderna expects to break even on an operating cash cost basis and generate $6 billion in revenue, with new product launches from 2026 to 2028 projected to yield a compounded annual growth rate of 25% or more [12] - Even with partial success in product launches, Moderna could achieve significant revenue growth over the next decade [13]

Core Viewpoint - ResMed (RMD) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Group 1: Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in a company's earnings picture, specifically tracking EPS estimates from sell-side analysts [1][2]. - A strong correlation exists between earnings estimate revisions and near-term stock price movements, making the Zacks rating system valuable for investors [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Group 2: ResMed's Earnings Outlook - ResMed is projected to earn $9.48 per share for the fiscal year ending June 2025, indicating no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for ResMed has increased by 0.2%, reflecting a positive outlook for the company's earnings [8]. Group 3: Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - ResMed's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [10].

Core Viewpoint - Hepion Pharmaceuticals has successfully transitioned to the OTCQB Venture Market, with its common stock trading under the symbol HEPA starting June 25, 2025 [1]. Company Overview - Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing diagnostic tests for various conditions, including celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori), and hepatocellular carcinoma (HCC) [2].

Core Viewpoint - Moderna has faced a significant decline in stock value, approximately 80% over the past three years, due to reduced demand for its coronavirus vaccine, despite recent positive developments in its product pipeline and cost-cutting measures [1][2][10]. Group 1: Company Performance - Moderna's revenue peaked at $18.4 billion in 2022 from its coronavirus vaccine, but demand has since dropped, leading to a decline in sales [5][10]. - The company has received approval for a second product, its respiratory syncytial virus (RSV) vaccine, but initial sales have been disappointing [2][6]. - Moderna aims to achieve between $1.4 billion and $1.7 billion in GAAP operating cost reductions by 2027 [7]. Group 2: Product Pipeline and Future Goals - Moderna has a robust late-stage pipeline with goals for up to 10 product approvals in the coming years, including multiple cancer vaccines [8][9]. - Currently, there are seven cancer-vaccine candidates in phase 2 or phase 3 studies, which could provide multiple revenue streams if successful [9]. - The company continues to focus on advancing its mRNA technology across various treatment areas, including latent viruses and cancer vaccines [4][5]. Group 3: Market Challenges and Investor Sentiment - Despite positive developments, investor sentiment remains cautious due to the ongoing decline in coronavirus vaccine sales and early disappointments in the RSV market [10][12]. - Uncertainty surrounding government vaccine policies may also pose challenges for Moderna's stock performance [11]. - Long-term prospects for revenue growth remain, particularly as key product approvals approach, suggesting potential for future stock appreciation [13][14].

Core Points - Danish Aerospace Company A/S (DAC) has signed a contract with the European Space Agency (ESA) to develop a prototype exercise device for the Lunar Gateway space station, which will eventually be used for human missions to Mars [1][3][8] - The Lunar Gateway is a collaborative project involving NASA, ESA, Japan, and Canada, with initial operations expected to begin around 2028 [2] - The contract is valued at approximately EUR 580,000 (DKK 4.3 million) and will last for about six months [7][8] Company Overview - DAC has over three decades of experience supplying exercise and medical monitoring equipment for space missions, including the Space Shuttle and the International Space Station (ISS) [3] - The company specializes in advanced medical instrumentation and engineering fields primarily within space applications [9][10] - DAC's products are based on extensive research and development, focusing on reliability in space environments [10][12] Project Details - Amentum Clean Energy will act as a subcontractor, contributing to the development of a vibration damping system to prevent exercise-induced vibrations from affecting the Lunar Gateway [4][5] - The new exercise device will incorporate a jumping exercise to enhance astronauts' bone, muscle, and cardiovascular health during space missions [4][8] - The prototype must meet unique requirements due to the higher background radiation and limited space in the HALO module compared to the ISS [6]

COMPANY ANNOUNCEMENT Odense, May 28, 2025 Company Announcement no. 60 – 28.05.2025 Danish Aerospace Company A/S and NECAS A/S enter strategic partnership to boost Danish defense and space technologyDanish Aerospace Company A/SCVR no.: 12424248 Danish Aerospace Company A/S (DAC) announces a strategic partnership with NECAS A/S aimed at strengthening Denmark’s technological capabilities and production capacity in the defense and space sectors. This partnership unites two of Denmark’s most specialized technol ...